Marathon Asset Management Ltd Lowers Position in Envista Holdings Corporation $NVST

Marathon Asset Management Ltd lessened its stake in Envista Holdings Corporation (NYSE:NVST) by 26.4% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 699,446 shares of the company’s stock after selling 250,561 shares during the quarter. Marathon Asset Management Ltd’s holdings in Envista were worth $14,248,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Raymond James Financial Inc. raised its holdings in shares of Envista by 10.7% in the 1st quarter. Raymond James Financial Inc. now owns 620,295 shares of the company’s stock worth $10,707,000 after purchasing an additional 60,030 shares during the period. Ieq Capital LLC acquired a new position in shares of Envista during the first quarter worth $752,000. State of Wyoming increased its stake in Envista by 121.1% during the 1st quarter. State of Wyoming now owns 16,911 shares of the company’s stock worth $292,000 after buying an additional 9,264 shares during the period. Magnetar Financial LLC purchased a new stake in Envista during the 1st quarter worth $1,151,000. Finally, Vident Advisory LLC acquired a new position in Envista in the 1st quarter worth $444,000.

Envista Stock Down 0.1%

NVST opened at $21.98 on Monday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.02 and a current ratio of 2.37. The company has a market capitalization of $3.61 billion, a PE ratio of 244.29, a P/E/G ratio of 1.08 and a beta of 1.02. The stock’s fifty day moving average is $20.60 and its 200-day moving average is $20.38. Envista Holdings Corporation has a one year low of $14.22 and a one year high of $22.68.

Envista (NYSE:NVST) last posted its quarterly earnings results on Wednesday, October 29th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.05. The company had revenue of $669.90 million for the quarter, compared to analysts’ expectations of $639.49 million. Envista had a return on equity of 5.90% and a net margin of 0.58%.The firm’s revenue was up 11.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.12 earnings per share. On average, equities analysts predict that Envista Holdings Corporation will post 1 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on NVST. Stifel Nicolaus set a $25.00 target price on Envista in a research report on Thursday, October 30th. Robert W. Baird set a $27.00 price target on shares of Envista in a report on Friday, October 31st. JPMorgan Chase & Co. raised their price objective on shares of Envista from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Tuesday, December 16th. Barclays started coverage on shares of Envista in a research note on Monday, December 8th. They issued an “overweight” rating and a $24.00 target price on the stock. Finally, Evercore ISI reaffirmed an “outperform” rating on shares of Envista in a research report on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Envista currently has a consensus rating of “Hold” and an average target price of $21.77.

Envista Profile

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.